What Comes After GLP-1 for Obesity? The Next Serious Waves
What comes after GLP-1 is not one thing. It is the combination of higher-ceiling receptor stacking, oral convenience, amylin-driven satiety strategies, and the few non-incretin assets that can actually become real products.
Why this matters
This is the broad framing question people ask when the market matures past first-wave GLP-1 excitement.
Current read
Retatrutide leads the ceiling story. Orforglipron leads the oral-access story. Amycretin and CagriSema lead the amylin extension story. Bimagrumab and a few others keep the non-incretin alternative story alive.
Primary query
what comes after glp1 for obesity
Page type
Pipeline Theme
Lead read
Retatrutide
Stage mix
3 phase 3 · 2 filed / decision-stage · 1 phase 2
Pipeline facts for search and AI answers
What this pipeline theme page answers
Primary query
what comes after glp1 for obesity
The page is built to answer this pipeline query directly before routing readers deeper.
Tracker type
Pipeline Theme
This page answers a focused pipeline question and connects it to the compounds, timelines, and comparisons that matter most.
Lead read
Retatrutide
Retatrutide leads the ceiling story. Orforglipron leads the oral-access story. Amycretin and CagriSema lead the amylin extension story. Bimagrumab and a few others keep the non-incretin alternative story alive.
Stage mix
3 phase 3 · 2 filed / decision-stage · 1 phase 2
FormBlends separates early pipeline interest from late-stage, filed, and approved assets.
Direct answer
What is it?
Retatrutide is a phase 3 program from Eli Lilly built around GLP-1/GIP/Glucagon.
Why does it matter?
What comes after GLP-1 is not one thing. It is the combination of higher-ceiling receptor stacking, oral convenience, amylin-driven satiety strategies, and the few non-incretin assets that can actually become real products.
What should you read next?
What we know right now
What comes after GLP-1 is not one thing. It is the combination of higher-ceiling receptor stacking, oral convenience, amylin-driven satiety strategies, and the few non-incretin assets that can actually become real products.
Retatrutide leads the ceiling story. Orforglipron leads the oral-access story. Amycretin and CagriSema lead the amylin extension story. Bimagrumab and a few others keep the non-incretin alternative story alive.
Right now this page is anchored by Retatrutide, Orforglipron, Amycretin (Zenagamtide), which is why the lane feels more concrete than a generic trend piece.
What is still uncertain
This topic already includes assets at approval or filing stage, so some of the commercial read is grounded in real regulatory progress rather than pure projection.
The next milestone is regulatory clarity. Once that lands, the conversation shifts quickly toward pricing, rollout, and access.
The biggest mistake in obesity pipeline content is treating strategic interest like commercial inevitability. This page is built to keep those two things separate.
Thesis
The next wave after first-generation GLP-1 is not a clean handoff from one winner to another. It is a fight between four practical upgrade paths: higher efficacy ceilings, easier access, better satiety layering, and genuinely different biology.
The real lanes after first-wave GLP-1
The market talks about "post-GLP-1" as if the category is waiting for one obvious successor. That is not how this looks in practice. The next serious wave is split between triple agonists like retatrutide, oral programs like orforglipron, amylin-linked assets like amycretin and CagriSema, and a much narrower set of non-incretin bets that could matter if they stop looking niche.
Those lanes solve different problems. Triple agonists are trying to raise the efficacy ceiling. Oral programs are trying to widen access and lower friction. Amylin programs are trying to improve satiety logic and create cleaner combination strategies. Non-incretin assets matter only if they unlock a use case that incretins are not handling well enough today.
What actually changes prescribing behavior
A lot of pipeline commentary still overweights novelty and underweights workflow. In real clinics, the drugs that change behavior are the ones that give physicians a cleaner reason to switch: more weight loss, easier adherence, better tolerability, more useful comorbidity coverage, or a lower-friction access story.
That is why retatrutide, orforglipron, CagriSema, and amycretin matter more than a long tail of interesting Phase 1 names. They are attached to real sponsor scale, real commercialization potential, and a believable reason the market would care once they move from story to product.
Where the category still looks fragile
The biggest risk in this whole topic is treating mechanism expansion like automatic progress. More receptor activity does not automatically mean better real-world medicine. It can also mean harder dose optimization, tougher tolerability, and a narrower group of patients who will actually stay on therapy.
The same caution applies to oral obesity drugs. A pill matters only if the efficacy stays competitive enough and the safety profile stays clean enough that physicians do not treat it like a convenient compromise. Convenience can widen the market, but it does not erase a weak product.
Which post-GLP-1 lanes look strongest right now
This is the cleaner strategic read, not a hype ranking.
| Lane or name | Why it wins | What can break |
|---|---|---|
| Triple agonists | This is still the clearest path to a higher efficacy ceiling, which is why retatrutide keeps leading the upside discussion. | The whole lane gets weaker fast if tolerability or safety turns the ceiling story into a niche story. |
| Oral GLP-1 and small molecules | This is the cleanest access story because a real pill can reset adoption, pricing pressure, and patient willingness to start therapy. | If efficacy looks too compromised next to injectables, the convenience story becomes less category-changing than people want it to be. |
| Amylin-pathway assets | This is the most credible satiety-extension lane and one of the few routes that could broaden the obesity toolkit without simple me-too repetition. | If the commercial read lands as portfolio extension rather than clear category upgrade, this lane stays important but not dominant. |
| Non-incretin challengers | This lane matters because the obesity market eventually needs alternatives that are not just more incretin engineering. | Most of these programs are still too early or too narrow to be treated as broad market leaders yet. |
What FormBlends is watching
- Which lane actually changes practice rather than just headlines
- Whether convenience starts mattering as much as efficacy
- How much room the market leaves for real alternatives to incretins
Decision path
How should I interpret What Comes After GLP-1 for Obesity? The Next Serious Waves?
This pipeline page is a decision aid for market context, not a patient access page. Use it to understand which mechanisms, companies, and trial stages are worth watching before comparing anything to available care.
- Topic
- what comes after glp1 for obesity
- Type
- Pipeline Theme
- Tracked names
- 6
- Stage mix
- 3 phase 3 · 2 filed / decision-stage · 1 phase 2
Step 1
Check maturity
This topic already includes assets at approval or filing stage, so some of the commercial read is grounded in real regulatory progress rather than pure projection.
Step 2
Watch the next signal
The next milestone is regulatory clarity. Once that lands, the conversation shifts quickly toward pricing, rollout, and access.
Open status hubStep 3
Compare to care today
Pipeline excitement should be separated from treatment decisions that require provider review, a legally available medication, and follow-up.
View current optionsHow this lane stacks up right now
A quick read on the compounds carrying the most weight on this page.
| Compound | Developer | Mechanism | Stage | Next step |
|---|---|---|---|---|
| Retatrutide | Eli Lilly | GLP-1/GIP/Glucagon | Phase 3 | Read status page |
| Orforglipron | Eli Lilly | Oral GLP-1 | FDA April 2026 | Read status page |
| Amycretin (Zenagamtide) | Novo Nordisk | GLP-1/Amylin | Phase 3 | Read status page |
| CagriSema | Novo Nordisk | GLP-1 + Amylin/Calcitonin | FDA-filed | Read status page |
| Bimagrumab | Eli Lilly/Versanis | ActRII antagonist | Phase 2b | Read status page |
| VK2735 | Viking Therapeutics | GLP-1/GIP | Phase 3 | Read status page |
Featured compounds in this lane
These are the names currently doing the real work in this part of the pipeline.
Non-incretin mechanisms
Bimagrumab
Eli Lilly/Versanis · Phase 2b
ActRII antagonist
Related comparisons
Retatrutide vs Orforglipron: Lilly's High-Efficacy Shot vs Its Access Play
Retatrutide is the bigger upside efficacy bet. Orforglipron is the bigger access and pricing bet. If you want to know which Lilly asset could change obesity treatment fastest at scale, it is orforglipron. If you want to know which one could most aggressively move the efficacy frontier, it is retatrutide.
Orforglipron vs Amycretin: Oral Scale Story vs Novo's Amylin-Franchise Bet
Orforglipron is the bigger broad-market adoption story. Amycretin is the bigger franchise strategy story. If the question is which asset could touch more patients faster, it is orforglipron. If the question is which one matters more to Novo's identity after the first wave, it is amycretin.
Retatrutide vs MariTide: Category-Leading Triple Agonist vs Amgen's Differentiation Bet
Retatrutide is the cleaner bet on late-stage leadership. MariTide is the cleaner bet on differentiated disruption. Retatrutide looks more obvious today. MariTide only wins this discussion if the market decides it wants something that feels genuinely different rather than merely stronger.
FormBlends separates trial-stage tracking from actual patient availability.
Late-stage, filed, and approved assets are treated differently from early exploratory programs.
This page is meant to answer the query fast, then route readers into compound, status, and comparison pages for deeper analysis.